Skip to content

Author

Wen-Yue Liu

We have 3 of 166 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease.

Lean MASLD represents a distinct phenotype with milder histologic disease but similar clinical outcomes compared with overweight/obese MASLD, and the FIB-4 demonstrated lower accuracy for predicting advanced fibrosis in lean vs overweight/obese MASLD.

L. de Avila, K. Al-Naamani, M. Papatheodoridi et al. · 1 citation
Sep 2026

Personalised prediction of the individual risk of liver-related events in MASLD using the dynamics of non-invasive tests.

By automatically integrating and interpreting the dynamics of non-invasive tests of liver fibrosis, JLCM enables the personalised prediction of the risk of hard outcomes, rather than the imperfect evaluation of histological surrogates.

C. Moreau, M. Roux, J. Riou et al. · 1 citation
Aug 2026

Activation of the KPNA2-mediated nuclear import of PPARα by KIF13B mitigates alcohol-associated liver steatosis.

This study identifies KIF13B as a novel regulator of hepatic lipid homeostasis in ALD via the KIF13B-KPNA2-PPARα axis, enhancing KPNA2 mediated nuclear import, particularly in combination with PPARα activation, represents a promising therapeutic strategy for ALD.

Kai-Kai Lu, Si Mei, Lian-Xing Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.